Back to search

Article

S100A9 Promotes Resistance to Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma by Degrading PARP1 and Activating the STAT3/PD-L1 Pathway

2025-01-14

Abstract excerpt

<title>Abstract</title> <p>Background Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death protein-1 (PD-1) immunotherapy, have emerged as promising treatments for advanced hepatocellular carcinoma (HCC), significantly improving clinical outcomes. However, resistance to ICIs remains a major challenge, and the underlying mechanisms of this resistance are not yet fully understood. This study aim...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7afdfc6d-7f3b-55c3-b259-0b208239a3d2
DOI
10.21203/rs.3.rs-5797937/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
S100A9 Promotes Resistance to Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma by Degrading PARP1 and Activating the STAT3/PD-L1 PathwayDOI 10.21203/rs.3.rs-5797937/v1
Select a neighboring publication to make it the new centre.